Equivac® EHV-1/4

Vaccine.

The vaccine is a killed vaccine containing equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4). It further contains thimerosal, polymyxin B and neomycin as preservatives.

Recommended for the vaccination of healthy horses as an aid in the prevention of equine rhinopneumonitis due to EHV type 1 and EHV type 4 viruses.

• Do not vaccinate horses intended for human consumption within 21 days of slaughter.

• Keep out of reach of children, uninformed persons and animals.

• Only healthy, immune competent horses should be vaccinated.

• Should an allergic reaction occur for any reason, intramuscular adrenaline should be administered.

• In any animal population, a small number of individuals may fail to respond to vaccination. Development of adequate immunity may also be altered by other conditions such as nutrition, disease and parasitism.

• In some instances, transient local reactions may occur at the injection site.

• Although this vaccine has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

• Shake well before and during use.

• Do not mix with other vaccines or products.

• Burn vaccine container and all unused contents. 

Use only as directed. 

Shake well before use. Use entire contents when first opened. Aseptically inject 1 ml deep intramuscularly per animal followed by a second vaccination 3 - 4 weeks after the first dose. An annual booster is recommended or in the event of a threatened epizootic. Horses subject to repeated exposure to field virus may benefit from revaccination with a single dose every three months.

Store in the dark between 2 - 7 °C. Refrigerate. Do not freeze.

10 x 1 ml (10 ml) doses per vial.

10 x 10 doses per bulk carton.